Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled

Affiliations

• ¹ Division of Cardiac Surgery, St Michael's Hospital, University of Toronto, Canada (S.V., N.K.D.).
• ² Baylor Scott and White Research Institute, Dallas, TX (J.B.).
• ³ Department of Medicine, University of Mississippi School of Medicine, Jackson (J.B.).
• ⁴ Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Germany (S.D.A.).
• ⁵ Université de Lorraine, Inserm, Centre d'Investigations Cliniques, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France (J.P.F., F.Z.).
• ⁶ Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Portugal (J.P.F.).
• ⁷ National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Greece (G.F.).
• ⁸ Division of Cardiology, Harvard Medical School and Massachusetts General Hospital, Boston (J.L.J.).
• ⁹ National Heart Centre Singapore, Duke-NUS Medical School (C.S.P.L.).
• ¹⁰ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK (N.S.).
• ¹¹ Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany (E.P.).
• ¹² Boehringer Ingelheim International GmbH, Ingelheim, Germany (M.N., M.B.).
• ¹³ First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Germany (M.B.).
• ¹⁴ Department of Medical Statistics, London School of Hygiene and Tropical Medicine, United Kingdom (S.J.P.).
• ¹⁵ Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).
• ¹⁶ Imperial College, London, United Kingdom (M.P.).